Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

age was 600 mg/day), and is more common in the elderly.

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Hepatotoxicity, occasionally severe, may occur. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment.

Patients with moderate renal impairment (CrCL = 20-39 mL/min) should receive a 50% decrease in the recommended starting dose, and future doses can be increased as tolerated. Doses greater than 600 mg/day are not recommended in patients with mild renal impairment (CrCL = 40-59 mL/min). For patients with moderate renal impairment, doses greater than 400 mg/day are not recommended. Gleevec should be used with caution in patients with severe renal impairment.

In the newly diagnosed CML trial, 2% of patients had (NCI Grades 3/4) hemorrhage.

There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure, and gastrointestinal (GI) perforation.

Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe patients able to tolerate the reintroduction of Gleevec at a lower dose with or without concomitant corticosteroids or antihistamines following resol
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 Today, ... honored 13 employees from 12 biopharmaceutical companies as ... efforts in policy advocacy and community service. ... Health Champion Awards were created by the biopharmaceutical ... excelled in their careers, but have also shown ...
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... the "Corporate Reputation of Pharma in 2014 - ... Edition" report to their offering. For ... opinions on the corporate reputation of the pharmaceutical industry ... health with the views of patient organisations representing all ...
(Date:4/16/2015)... , April 16, 2015 Vanda Pharmaceuticals ... focused on the development and commercialization of products for ... it will release results for the first quarter of ... closes. The Company will host a ... 6, 2015, during which Vanda management will discuss the ...
Breaking Medicine Technology:PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2
... Dec. 22, 2010 Haemonetics Corporation (NYSE: ... Chief Executive Officer, will present at the J.P. Morgan ... 2011 at 1:30 pm Pacific time.  The ... at http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=HAE .  The webcast ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... update webcast/conference call after the market closes on January ... Vicente Anido, Jr., Ph.D., and Chief Financial Officer and ... 2011 guidance, give a commercial and new product pipeline ...
Cached Medicine Technology:ISTA Pharmaceuticals Announces 2011 Guidance and Pipeline Update Webcast/Conference Call on January 5, 2011 2
(Date:4/18/2015)... 18, 2015 "I wanted to ... create a healthful juice that contained essential vitamins, ... Md. "It increases my energy, improves skin elasticity ... He developed Tapp's Juice to contain fruits, vegetables ... prevent physical and mental fatigue. It features a ...
(Date:4/18/2015)... has released a new blog post explaining how to ... , Drivers can find accurate information about various auto ... website can help drivers compare the newest and best ... whole process is designed to be convenient, free and ... quotes is advantageous because it allows clients to find ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 More than ... sale now at TheCelebrityDresses.com, the #1 online store carrying ... ongoing many girls have got their perfect dresses for ... the celebrity fashion prom dresses at TheCelebrityDresses.com would be ... designed more than 2000 prom dresses inspired by the ...
(Date:4/18/2015)... 2015 PHOENIX, ARIZONA – In March, ... 11 other secure destruction professionals across the United States, ... He will now display “CSDS” as a professional title ... the National Association of Information Destruction 2015 Annual Conference ... Texas. Of the 20 people who took the exam, ...
(Date:4/17/2015)... 2015 Rosetta Radiology is proud to ... their list of diagnostic imaging services. This solidifies them ... the Upper East Side of Manhattan. , The new ... The addition of PET-CT, combined with Rosetta’s state of ... to work with patients through several stages of the ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2
... American Society,for Therapeutic Radiology and Oncology is pleased to ... Oriental Republic of,Uruguay, will present a special guest lecture ... 1 in Los Angeles. Dr. Vazquez, who,is a radiation ... speak October 30 at 9:00 a.m. at the Los ...
... but not all , WEDNESDAY, Oct. 17 (HealthDay News) -- ... pain. , That,s the conclusion of Israeli researchers who reviewed ... insoles to sham insoles or no treatment for back pain ... of 256 people that focused on the use of insoles ...
... Help Advance Research-, MISSION VIEJO, Calif., Oct. ... for its innovative genomic search,technology, SLIM Search(TM), Inc. ... The SLIM Search genomic search tool delivers greater ... 1.3 includes the following features: * ...
... 17 After completing its review of safety,and ... Board (DSMB) has recommended that the pivotal Phase ... Edema) Study,continue under the current protocol, without change. ... for the treatment of diabetic macular edema (DME). ...
... Oct. 17 IRIDEX,Corporation (Nasdaq: IRIX ) announced ... and Chief Executive Officer, and as a member of,the ... The Board of,Directors has appointed Theodore A. Boutacoff, who ... Directors, to serve as the Company,s President,and Chief Executive ...
... - For the Nine Months (to 31 August) a 46% Sales ... in EBIT to EUR34.8m (EUR6.2m) - Marked Improvement in Adjusted ... Fall in Interest Charges Since the IPO - CEO Dr. ... In the first nine months of its financial year (to ...
Cached Medicine News:Health News:President of Uruguay to Speak at ASTRO Annual Meeting 2Health News:Release 1.3 of SLIM Search Now Available 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 3Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 4Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 2Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 3Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 4Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 5
... cool-running, energy efficient LEDs (Light Emitting Diodes) ... see without affecting the darkened refracting environment. ... free so you'll never need to change ... a limited lifetime warranty, the best in ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
10 (mm) smooth platform; Serrated handle in stainless steel....
Compatible with the Volcano Therapeutics Trak Back II Disposable Catheter Pullback Device,and the Volcano Therapeutics In-Vision Imaging System....
Medicine Products: